Form 8-K - Current report:
SEC Accession No. 0001104659-25-062639
Filing Date
2025-06-25
Accepted
2025-06-25 17:22:03
Documents
13
Period of Report
2025-06-24
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2519011d1_8k.htm   iXBRL 8-K 28805
2 EXHIBIT 3.1 tm2519011d1_ex3-1.htm EX-3.1 8651
  Complete submission text file 0001104659-25-062639.txt   206005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clrb-20250624.xsd EX-101.SCH 3017
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20250624_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20250624_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2519011d1_8k_htm.xml XML 3685
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 251074553
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)